Tech Company Financing Transactions
Blaze Bioscience Funding Round
Blaze Bioscience closed a $3.5 million Series A financing round on 2/22/2013. Backers included private investors.
Transaction Overview
Company Name
Announced On
2/22/2013
Transaction Type
Venture Equity
Amount
$3,500,000
Round
Series A
Investors
Proceeds Purpose
The funding (an add-on to previously raising $5 million in its Series A) will support the advancement of Blaze's Tumor PaintTM product candidate, BLZ-100, into clinical development for use in surgery in multiple solid tumor types. The resources have also supported the expansion of Blaze's leadership team and establishment of corporate headquarters, including laboratory space, in the South Lake Union area of Seattle.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
530 Fairview Ave. North 1400
Seattle, WA 98109
USA
Seattle, WA 98109
USA
Phone
Website
Email Address
Overview
Blaze has taken on this inspiration as we meet the challenge of moving quickly to advance our first Tumor Paint product candidate, BLZ-100, through clinical trials and onto the market where we believe it will eventually help millions of cancer patients.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Heather Franklin
VP - Bus. Development
Dennis Miller
VP - Finance
Mila Lobanova
VP - Manufacturing
Claudia Jochheim
VP - Operations
Laura Ishak
VP - R & D
Julia Novak
Browse more venture capital transactions:
Prev: 2/22/2013: Sanguine BioSciences venture capital transaction
Next: 2/22/2013: Celmatix venture capital transaction
Share this article
About Database of VC Transactions
Our team works diligently to document funding rounds that are announced publicly. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs